Biocon Biologics Signed a Settlement and Licence Agreement

News Desk, News Nation 360 : Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, has announced a new settlement and licence agreement with Regeneron and Bayer for biosimilar Aflibercept (40mg/ml) in Europe and the rest of the world, following an earlier agreement covering the United States and Canada. Biocon Biologics has reached a settlement and license agreement with Regeneron and Bayer, concluding all pending litigation and enabling global commercialisation of Yesafili®, its biosimilar aflibercept (40mg/ml), a VEGF inhibitor for ophthalmic disorders such as wet AMD, DME, RVO, and myopic CNV. The agreement provides for launches in the UK in January 2026 and in other settled countries in March 2026 (or earlier under certain conditions), building on previous accords with the US and Canada (US entry in H2 2026, with Canada launched earlier). Yesafili has received EC and MHRA approval, marking Biocon's foray into ophthalmology with its tenth commercialised biosimilar, benefiting over 6.3 million patients in 120 countries. Shreehas Tambe, CEO and Managing Director, Biocon Biologics, stated that this agreement sets the path for Biocon Biologics to distribute our biosimilar Aflibercept globally. This milestone strengthens their position in the ophthalmology therapeutic area, as they collaborate with healthcare institutions to improve patient access globally.

Pic - Courtesy